-
2025-521632-12-00
5
Patients on Factor Xa inhibitor treatment needing an urgent interventi
-
2025-524498-17-00
10
2026-05-08
Pretreated Unresectable Locally Advanced or Metastatic human epidermal
-
2025-522191-86-00
5
2026-04-02
Focal segmental glomerulosclerosis
-
2024-516646-19-00
5
2025-08-15
Type 2 diabetic patients with no prior cardiovascular (CV) events
-
2024-512360-55-00
4
2025-06-30
Unresectable locally recurrent or metastatic hormone receptor (HR)-pos
-
2023-504918-29-00
5
2024-08-22
Hormone receptor positive breast cancer
-
2023-507129-40-00
4
2024-08-06
interstitial lung disease secondary to systemic sclerosis (SSc-ILD)
-
2025-521188-11-00
5
2025-10-15
Type 2 diabetes
-
2024-515561-34-01
6
2025-08-04
Acute ischemic stroke with recent ingestion of direct oral anticoagula
-
2024-512161-14-00
3
2025-01-14
Breast Cancer
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.
-
2023-507914-28-00
10
2024-06-19
Platinum-resistant, high-grade serous ovarian cancer (OVC),high-grade
-
2023-504031-41-00
5
2024-03-25
ER+/HER2- Early Breast Cancer
-
2024-515871-37-00
5
2024-10-24
Moderate to severe systemic lupus erythematosus
-
2022-501172-25-00
5
2024-01-17
Chronic and Episodic Migraine
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-500700-22-00
5
2023-05-25
Active Systemic Lupus Erythematosus (SLE)
-
2022-501608-85-00
5
2023-05-09
Cardiovascular disease (atherosclerotic cardiovascular disease (ASCVD)
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2023-509923-42-00
4
2017-07-06
HER2- positive breast cancer
-
2024-512505-66-00
10
2025-03-03
HIV-1 Infection
-
2023-503793-20-00
5
2023-01-18
Prevention of ischemic stroke in patients post acute non-cardioembolic
-
2022-501132-42-00
6
2022-08-02
Monkeypox virus disease